Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $133,827.98 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $133,827.98. Following the transaction, the insider owned 1,161,128 shares in the company, valued at approximately $9,323,857.84. This represents a 1.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, June 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.06, for a total value of $101,002.02.
• On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.23, for a total value of $103,835.41.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $8.28 on Friday. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The company has a market cap of $1.43 billion, a PE ratio of 138.00 and a beta of 0.62. The business has a 50 day moving average of $6.61 and a 200 day moving average of $6.63. Xeris Biopharma Holdings, Inc. has a 52 week low of $4.62 and a 52 week high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The company had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. As a group, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds have recently modified their holdings of XERS. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma during the fourth quarter valued at about $25,000. KBC Group NV bought a new position in shares of Xeris Biopharma during the first quarter worth $27,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after purchasing an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after buying an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on XERS. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.